Acenocoumarol
- Generic Name
- Acenocoumarol
- Drug Type
- Small Molecule
- Chemical Formula
- C19H15NO6
- CAS Number
- 152-72-7
- Unique Ingredient Identifier
- I6WP63U32H
- Background
Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients on acenocoumarol are prohibited from giving blood.
- Indication
For the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.
- Associated Conditions
- Coronary Occlusions, Pulmonary Embolism, Systemic Embolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
- Conditions
- Pulmonary Embolism
- First Posted Date
- 2003-06-17
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00062803
- Locations
- 🇺🇸
Loyola University Medical Center and Outpatient Clinic, Maywood, Illinois, United States
🇺🇸Akron General Medical Center, Akron, Ohio, United States
🇺🇸Mary Black Memorial Hospital, Spartanburg, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.